The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review.

IF 3.1 Q2 ONCOLOGY

Oncology Reviews Pub Date : 2021-11-26 eCollection Date: 2021-09-21 DOI:10.4081/oncol.2021.547

Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti

{"title":"The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review.","authors":"Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti","doi":"10.4081/oncol.2021.547","DOIUrl":null,"url":null,"abstract":"<p><p>Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib and nilotinib on blood potassium and calcium levels. It also summarized their hypothetical mechanism. A comprehensive electronic search of the different databases was conducted using 'chronic myeloid leukemia', 'tyrosine kinase inhibitors', 'imatinib', 'nilotinib', 'potassium', 'calcium', 'electrolytes' as keywords. This review used PubMed- MEDLINE, Cochrane Library, and Google Scholar as the source databases. Sixteen articles published from 2006 to 2020 were reviewed. Changes in blood potassium levels range from increased to decreased levels, while changes in blood calcium levels range from the lower normal values to below normal values (hypocalcemia). Tyrosine kinase inhibitors (TKIs), including imatinib and nilotinib, have a non-specific target, namely plateletderived growth factor receptor (PDGFR), which indirectly affects blood potassium and calcium levels in CML patients. The clinical manifestations of these changes vary from being visible only in laboratory tests to displaying a variety of clinical signs and symptoms.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 2","pages":"547"},"PeriodicalIF":3.1000,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/a0/onco-15-2-547.PMC8649642.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2021.547","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/21 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib and nilotinib on blood potassium and calcium levels. It also summarized their hypothetical mechanism. A comprehensive electronic search of the different databases was conducted using 'chronic myeloid leukemia', 'tyrosine kinase inhibitors', 'imatinib', 'nilotinib', 'potassium', 'calcium', 'electrolytes' as keywords. This review used PubMed- MEDLINE, Cochrane Library, and Google Scholar as the source databases. Sixteen articles published from 2006 to 2020 were reviewed. Changes in blood potassium levels range from increased to decreased levels, while changes in blood calcium levels range from the lower normal values to below normal values (hypocalcemia). Tyrosine kinase inhibitors (TKIs), including imatinib and nilotinib, have a non-specific target, namely plateletderived growth factor receptor (PDGFR), which indirectly affects blood potassium and calcium levels in CML patients. The clinical manifestations of these changes vary from being visible only in laboratory tests to displaying a variety of clinical signs and symptoms.

Abstract Image

查看原文本刊更多论文

伊马替尼和尼洛替尼对慢性髓系白血病患者血钙、血钾水平的影响:文献综述。

伊马替尼和尼洛替尼是慢性髓性白血病(CML)患者的一线治疗药物，它们对靶细胞起特异性作用。然而，这些药物可能会引起副作用，如电解质紊乱。本文献综述旨在比较伊马替尼和尼洛替尼对血钾和钙水平的影响。文中还总结了它们的假设机制。以“慢性髓性白血病”、“酪氨酸激酶抑制剂”、“伊马替尼”、“尼罗替尼”、“钾”、“钙”、“电解质”为关键词，对不同的数据库进行了全面的电子搜索。本综述使用PubMed- MEDLINE、Cochrane Library和Google Scholar作为源数据库。对2006 ~ 2020年发表的16篇论文进行综述。血钾水平的变化范围从升高到降低，而血钙水平的变化范围从较低的正常值到低于正常值(低钙血症)。酪氨酸激酶抑制剂(TKIs)，包括伊马替尼和尼罗替尼，具有非特异性靶点，即血小板衍生生长因子受体(PDGFR)，间接影响CML患者的血钾和钙水平。这些变化的临床表现各不相同，从仅在实验室检查中可见到表现出各种临床体征和症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Reviews ONCOLOGY-

CiteScore

6.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.